Ablation and Isolation for Persistent Atrial Fibrillation Treatment
Official title: Convergent Ablation Plus Left Atrial Appendage Isolation for the Treatment of Persistent Atrial Fibrillation
Run by Barts & The London NHS Trust · NCT06165510 · Data updated 2026-11-12
This study is testing a new two-step treatment for long-lasting atrial fibrillation to see if it works better than the standard method and helps patients need fewer medications.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 48 (estimated) |
| Sponsor | Barts & The London NHS Trust Academic / other |
| Locations | 1 site (London) |
| Status | Recruiting |
| Started | August 2, 2024 |
| Main results expected | November 1, 2026 |
| Study ends | November 2026 |
| Registry record updated | June 25, 2026 |
| Trial ID | NCT06165510 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 to 80 with persistent atrial fibrillation lasting over one year.
✕Probably not a fit
Patients with reversible causes of atrial fibrillation, significant valve disease, or prior cardiac surgeries may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial evaluates the effectiveness of a hybrid approach combining convergent ablation with the LARIAT procedure against standard endocardial catheter ablation in patients suffering from long-standing persistent atrial fibrillation. The study involves a two-stage minimally invasive procedure where the first stage includes surgical ablation and left atrial appendage isolation, followed by endocardial catheter ablation to enhance treatment outcomes. Participants will be randomly assigned to one of the two treatment groups to assess safety and efficacy. The goal is to improve success rates and reduce the need for anti-arrhythmic medications.
Why it matters
Potential benefit: If successful, this approach could significantly enhance patient quality of life and reduce hospital readmission rates.
How similar studies have gone: While the approach is innovative, previous studies have shown mixed results with standard catheter ablation, indicating a need for improved methods.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \> 18 years; \< 80 years * Persistent AF \> 1-year duration * Left atrium size \< 6cm * Pts should be able to provide written informed consent. Exclusion Criteria: * Subjects currently enrolled in another investigational study except in case of observational registry with no associated treatments. * Subject has a reversible cause of AF or transient AF * Subject is absent of LAA or if the LAA is previously surgically ligated * Subject has had previous cardiac surgery or abdominal surgery. * Subject has contraindication to anticoagulation. * Patients with hypertrophic cardiomyopathy. * Patients with significant valve disease. * Subject has had previous catheter or surgical ablation
Where it's running
-
St Bartholomew's Hospital
London, United Kingdom Recruiting
Study contacts
- Principal investigator: Syed Ahsan — Consultant Cardiologist and Electrophysiologist, Barts Health NHS Trust
- Study coordinator: Syed Ahsan
- Email: syedahsan@nhs.net
- Phone: 020 7377 7000
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Hybrid ablation for treating persistent atrial fibrillation
This study is testing a new hybrid treatment for people with persistent atrial fibrillation to see if it works better than the standard catheter procedure in helping them stay free from heart rhythm problems.
-
Comparing anticoagulants for patients with atrial fibrillation and severe kidney disease
This study is testing whether different blood-thinning medications can help people with atrial fibrillation and severe kidney disease stay healthier and avoid complications.
-
Personalized ablation strategies for atrial fibrillation
This study is testing personalized treatment plans for people with persistent atrial fibrillation to see if tailored catheter ablation can improve their heart rhythm and treatment success.
-
Atrial Arrhythmia AI-Powered Post-Ablation Predictor Pilot
This pilot study tests whether AI models using non-invasive heart-mapping data can predict how patients with atrial arrhythmias respond after ablation.
-
Volta AI software in real-world AF ablation
A real-world observational study will test the latest Volta AF-Xplorer II AI software during atrial fibrillation ablation to see how safe and effective it is over 24 months.
-
FARAFLEX Mapping and Pulsed Field Ablation for Atrial Fibrillation
This trial tests the FARAFLEX Mapping and PFA System to see if it can safely help adults with drug-refractory paroxysmal or persistent atrial fibrillation.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.